The biggest risks in pharmaceutical cold chain transport are the points where a shipment can drift outside its approved temperature range: long dwell times, multiple handoffs, equipment or power failures, external temperature extremes, and delays that outlast the packaging. Any one of them can turn a valuable, temperature-sensitive shipment into a total loss.
A temperature-controlled medicine is valuable, fragile, and often traveling a long way, and transport is where it spends the most time exposed to conditions no single party fully controls. A growing share of the pharmaceutical pipeline is made up of biologics, cell and gene therapies, and vaccines, which hold efficacy only inside a narrow band — commonly 2–8°C for refrigerated products, 15–25°C for controlled room temperature, and −20°C or below for frozen material. A few hours outside that band can cut a product's shelf life or end it.
The scale of the loss is well documented. The IATA CEIV Pharma program, drawing on Pharmaceutical Commerce data, estimates that between US$2.5 billion and US$12.5 billion of pharmaceutical product is lost every year to temperature excursions, against a cold chain market worth around US$300 billion annually. More recent industry estimates have put the figure far higher, at roughly US$35 billion a year once the full cost of failures is counted.
The risk concentrates in specific moments, and most of them happen on the ground.
Most failures trace back to a handful of recurring risks. Taken in order of how often they cause an excursion, these are the ones that matter most.
Dwell time is the single largest source of risk. IATA CEIV Pharma reports that over 50% of all temperature excursions occur while products are in the hands of airlines and airports — the hours a shipment spends waiting, not the hours it spends flying.
The reason is that ground time is where temperature control is weakest. A pallet can sit on an open tarmac waiting to be loaded or collected, where surface temperatures on a sunny apron can climb well above 50°C, or wait in a transit shed that is kept comfortable for staff but warmer than the product's set point. Active, powered containers compete for a limited number of power points on the ground, and a unit left unplugged runs on battery it was meant to conserve for the flight. Add missed connections and congestion at major hubs, and dwell becomes the longest, least-controlled, and riskiest part of the lane. (SkyCell covers this in depth in Why Airport Dwell Time Is the Biggest Risk in Pharma Logistics.)
A single international shipment can change hands many times: manufacturer, freight forwarder, trucking company, airline ground handler, the airline itself, a second ground handler on arrival, a customs broker, and the final courier. Every transfer is a point where a shipment can be left on a dock, loaded late, stored at the wrong temperature, or repackaged by a party that does not know its requirements.
Handoffs also diffuse accountability. When ownership of the shipment passes from party to party with no single organization responsible end to end, a container that sits too long between two of them falls into a gap that each assumes the other is watching. This is why handoffs rank alongside dwell time as a leading cause of excursions: they are the seams of the journey, and the seams are where control is lost.
Active containers and refrigerated units hold temperature using compressors, batteries, and power. That protection lasts only as long as the power does. A depleted battery, a missed recharge during a long dwell, a tripped unit, or a mechanical fault can end temperature control mid-journey, often while the shipment moves on and the fault stays hidden until it is opened.
Deep-frozen shipments carry a related risk: dry ice sublimates over time, so a shipment that is delayed can run out of refrigerant before it arrives. Passive and hybrid containers remove some of this exposure by holding temperature without external power, but any system has a defined limit, which leads to the next risk.
Every container is rated to hold temperature for a fixed period. A delay shorter than that rating is absorbed; a delay longer than it becomes an excursion. The danger is that real-world journeys routinely run longer than planned — customs inspections, missed connections, strikes, weather diversions, and public holidays all add time beyond what the packaging was built to cover.
A shipment planned as a 48-hour door-to-door move, protected by packaging rated for 48 hours, has no margin for the delay that cold chains see all the time. The gap between the planned journey and the realistic worst-case journey is where runtime risk lives, and it is why margin matters more than a nominal match to the schedule.
Ambient conditions along the lane put constant stress on packaging. Tropical heat and humidity, sub-zero winters, and hot tarmacs push a container toward its limits, and a lane that crosses several climates in one journey can swing from one extreme to the other. Summer and winter peaks, and routes through hot or remote regions with limited cold chain infrastructure, are where ambient stress most often tips a shipment into an excursion.
Packaging that performs well on a temperate European lane can fail on a Gulf or equatorial route in August if the lane was planned for milder conditions. Ambient extremes usually work as a multiplier on the other risks, shrinking the margin each of them eats into.
A temperature breach is only actionable if someone knows about it in time. With traditional data loggers that are read on arrival, an excursion is discovered after the fact, when the only decision left is whether to release or destroy the product. Real-time monitoring changes what is possible: a live temperature and location feed lets a team re-ice, re-route, expedite, or escalate while the shipment is still recoverable.
The real risk here is the lost window to respond. A breach caught in the air can sometimes be saved on the ground; the same breach discovered at the destination is usually past saving.
Good Distribution Practice requires a continuous, verifiable temperature record for every shipment. A gap in that record is a risk in its own right: a shipment whose product stayed in range can still be quarantined or rejected if the data is missing, inconsistent, or cannot be reconciled across the parties that handled it. For some markets and products, a documentation failure is treated the same as a temperature failure.
This risk is easy to overlook because it sits apart from the physical condition of the product. A documentation gap can still strand a healthy batch in quarantine and delay patients just as effectively as a real excursion.
The most costly failures combine a demanding lane with a fragile, high-value product. A long, delay-prone route carrying a biologic concentrates several of the risks above at once, so an excursion that a short, robust lane would absorb becomes a total loss. A single spoiled batch of a high-value biologic can be worth millions, before counting the downstream cost.
Across a network, dwell time and handoffs are consistently the largest contributors, because they are where shipments sit exposed and change hands — the two conditions that turn a manageable risk into a failure.
Cold chain risk is easy to underestimate because most shipments arrive intact, and the failures that do happen are scattered across different lanes, products, and causes, so no single pattern stands out. Survivorship creates false confidence: a lane that has worked for a year can still fail the first time a heatwave meets a customs hold.
The cost of a single failure reaches well beyond the lost product — into delayed patient treatment, investigation and root-cause work, regulatory exposure, and lost supply that can take months to replace. Averaged across a network, even a low excursion rate adds up to a large annual number, which is how the industry arrives at multi-billion-dollar loss estimates.
Reducing risk depends on choosing packaging with margin, planning the lane, and keeping the shipment visible.
SkyCell addresses cold chain transport risk with packaging that holds temperature longer and software that makes risk visible. The figures below are drawn from SkyCell's published data.
The biggest risks in cold chain transport cluster around time and handoffs: the hours a shipment waits and the moments it changes hands. More than half of excursions happen on the ground, in the hands of airlines and airports, so the measures that address dwell, handoffs, runtime, and visibility address the bulk of the risk.
Because the same measures that prevent excursions also cut waste and delay, reducing transport risk tends to improve reliability and cost together.
As pharmaceutical shipments grow more valuable and more temperature-sensitive, understanding the biggest risks in cold chain transport becomes increasingly important. The questions below cover the points that matter most.
The biggest risks are long dwell times at airports and warehouses, handoffs between parties, equipment or power failure, delays that outlast the packaging's runtime, external temperature extremes, excursions that go unnoticed without monitoring, and incomplete temperature documentation.
Most failures happen where shipments sit exposed or change hands, especially during airport and warehouse dwell time and at handoffs between manufacturer, forwarder, airline, and ground handler.
Shipments often wait longest on tarmacs and in transit warehouses, where temperature control is weakest. Heat or cold can build up during these waits, and a delay longer than the packaging's runtime leads to an excursion.
Beyond the lost product, a failure delays patient treatment, triggers investigation and root-cause work, creates regulatory exposure, and can cause lost supply. For high-value biologics, a single spoiled batch can be worth millions.
By using packaging with runtime margin beyond the planned journey, reducing handoffs with containers that cross modes without repackaging, monitoring temperature and location in real time, assessing the lane before shipping, and keeping complete records.
SkyCell's hybrid containers hold temperature without external power for long periods (270 hours at +20°C on the 1500X, 300 hours on the 6500X) and cross modes without repackaging, with an independently assessed excursion rate below 0.05%. Validaide adds real-time visibility and lane risk assessment across more than 250 monitored airports.